Stabilized synthetic immunogen delivery system

Details Stabilized synthetic immunogen delivery system Stabilized synthetic immunogen delivery system

2003-05-21

2011-12-27

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to cyclopentano-hydrophenanthrene ; derivative thereof

C424S001530, C424S001650, C424S001730, C424S185100, C514S04400A

Reexamination Certificate

active

08084015

ABSTRACT:
The present invention provides an immunostimulatory complex specifically adapted to act as adjuvant and as a peptide immunogen stabilizer. The immunostimulatory complex comprises a CpG oligonucleotide and a biologically active peptide immunogen. The immunostimulatory complex is particulate and can efficiently present peptide immunogens to the cells of the immune system to produce an immune response. The immunostimulatory complex may be formulated as a suspension for parenteral administration. The immunostimulatory complex may also be formulated in the form of w/o-emulsions, as a suspension in combination with a mineral salt suspension or with an in-situ gelling polymer for the efficient delivery of an immunogen to the cells of the immune system of a subject following parenteral administration, to produce an immune response which may also be a protective immune response.

REFERENCES:
patent: 4938763 (1990-07-01), Dunn et al.
patent: 5126141 (1992-06-01), Henry
patent: 5135751 (1992-08-01), Henry
patent: 5149543 (1992-09-01), Cohen et al.
patent: 5562909 (1996-10-01), Allcock et al.
patent: 5656611 (1997-08-01), Kabanov et al.
patent: 5700459 (1997-12-01), Krone et al.
patent: 5702716 (1997-12-01), Dunn et al.
patent: 5759551 (1998-06-01), Ladd et al.
patent: 5763160 (1998-06-01), Wang
patent: 6025468 (2000-02-01), Wang
patent: 6090388 (2000-07-01), Wang
patent: 6107021 (2000-08-01), Wang et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6312731 (2001-11-01), Staas et al.
patent: 6471996 (2002-10-01), Sokoll et al.
patent: 6573238 (2003-06-01), Shirley et al.
patent: 6623764 (2003-09-01), Sokoll et al.
patent: 6780969 (2004-08-01), Wang
patent: 6902743 (2005-06-01), Setterstrom et al.
patent: 7488490 (2009-02-01), Davis et al.
patent: 2003/0026801 (2003-02-01), Weiner et al.
patent: 2003/0027979 (2003-02-01), Wang
patent: 2003/0055014 (2003-03-01), Bratzler
patent: 2003/0068325 (2003-04-01), Wang
patent: 2003/0165478 (2003-09-01), Sokoll
patent: 2004/0009897 (2004-01-01), Sokoll
patent: 2004/0185055 (2004-09-01), Glenn et al.
patent: 2004/0202680 (2004-10-01), O'Hagan
patent: 2005/0059619 (2005-03-01), Krieg et al.
patent: 2005/0079185 (2005-04-01), Parisot et al.
patent: 2005/0163745 (2005-07-01), Sokoll et al.
patent: 2005/0191319 (2005-09-01), O'Hagan et al.
patent: 2005/0208143 (2005-09-01), O'Hagan et al.
patent: 2005/0250726 (2005-11-01), Krieg et al.
patent: 2006/0002959 (2006-01-01), Glenn et al.
patent: 2396884 (2001-08-01), None
patent: WO 91/04052 (1991-04-01), None
patent: WO 93/01286 (1993-01-01), None
patent: WO 94/25060 (1994-11-01), None
patent: WO 99/52549 (1999-10-01), None
patent: WO 99/66950 (1999-12-01), None
patent: WO 99/66957 (1999-12-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/50006 (2000-08-01), None
patent: WO 01/22972 (2001-04-01), None
patent: WO 01/93903 (2001-12-01), None
patent: WO 01/93905 (2001-12-01), None
patent: WO 01/97843 (2001-12-01), None
patent: WO 03/068169 (2003-08-01), None
Nesburn et al, Vaccine, 2005, 23:873-883.
O'Hagan, Current Drug—Targets Infectious Disorders, 2001, 1:273-286.
Stern et al, J Immunology, 2002, 168:6099-6105.
Maurer et al, Eur. J. Immunol. 2002, 32:2356-2364.
Singh et al, Pharmaceutical Research, Jun. 2002, 19/6:715-728.
O'Hagan et al, Biomolecular Engineering.
Singh et al, International J. Parasitology, 2003, 33:469-478.
O'Hagan, Current Drug Targets-Infectious Disorders, 2001, 1:273-286.
Dittmer et al, Current Opinion in Microbiology, 2003, 6:472-477.
Yoshinaga et al, Immunology, 2006, 120:295-302.
Riedl et al, J. Mol. Med., 2004, 82:144-152.
Diminsky et al, Vaccine, 2000, 18:3-17.
Morita et al, International J. Pharmaceutics, 2001, 219:127-137.
Ivins et al, Vaccines, 1995, 13/18:1779-1784.
Gupta et al, Vaccine, 1997, 15(6/7):672-678.
Hakim et al.,J. Immunol., 1996; 157:5503-5511.
Zeng et al.,Theriogenology, 2002; 58:1315-1326.
Proietti et al.,J. Immunol., 2002; 169:375-383.
OIE Manual of Standards for Diagnostic Tests and Vaccines, Chap. 2.1.1, “Foot and Mouth Disease”, 1997.
European Search Report for corresponding European Patent Application No. 037091345-1222 (PCT/US03/04711), dated Apr. 1, 2008.
Shieh et al., “Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization”,Vaccine, (2001); 19:4002-4010.
Jones et al., “Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys”,Vaccine, (1999); 17:3065-3071.
Aguado MT, et al.,Immunobiol, 1992, 184:113-125.
Aguiar JC, et al.Vaccine, 2002, 20:275-280.
Akasaka T, et al.,Bioconjugate Chem., 2001, 12:776-785.
Ballico M, et al.,Bioconjug Chem, 2001, 12:719-725.
Bjellqvist B, et al.,Electrophoresis, 1993, 14:1023-1031.
Chu RS, et al.,J Exp Med, 1997, 186:1623-1631.
Cox JC, et al.Vaccine, 1997, 15:248-256.
DesNoyer JR, et al.,J Controlled Release, 2001, 70:285-294.
Eldridge JH, et al.,Mol Immunol,1991, 28:287-297.
Forbes RT, et al.,J Pharm Sci,1998, 87:13161321.
Graham PD, et al.,J Controlled Release,1999, 58:233-245.
Hanson CV, et al.,J. Clin Microbiol,1990, 28:2030-2034.
Higaki M, et al.,Vaccine,1998, 16:741-745.
Hilbert AK, et al., Vaccine, 1999, 17:1065-1073.
Ikada Y, et al.,J Bioactive Compat Polym,1986, 1:32-46.
Jepson MA, et al.J Drug Targeting,1993, 1:245-249.
Jones TR, et al.,Vaccine,1999, 17:3065-3071.
Kabanov AV, et al.,Bioconjug Chem,1995, 6:7-20.
Klinman DM, et al.,Vaccine,1999, 17:19-25.
Klinman DM, et al.,Infect Immun,1999, 67:5658-5663.
Kreuter J, et al.Vaccine,1986, 4:125-129.
Krieg AM, et al.,Nature1995, 374:546-549.
LiCalsi C, et al.,Vaccine,1999, 17:1796-1803.
MacDonald RC, et al.,Biochim Biophys Acta,1991, 1061:297-303.
Manning MC, et al.Pharmaceutical Research,1989, 6:903-918.
Mascotti DP, et al.,Proc Nat Acad Sci,USA, 1990, 87:3142-3146.
Matsuo K, et al.Vaccine,2000, 18:1344-1350.
McCluskie MJ, et al.,Vaccine,2000, 18:231-237.
Moldoveanu Z, et al.,J Infect Dis,1993, 167:84-90.
Monfardini C, et al., Bioconjugate Chem., 1998, 9:418-450.
Nagel KM, et al.,Pharmacotherapy,1993, 13:177-188.
Overcashier DE, et al.,J Pharm Sci,1999, 88:688-695.
Papisov IM, et al.,Advances in Polymer Science,1988, 90, 1988,139-177.
Park TG, et al.,J Controlled Release,1995, 33:211-222.
Powell MF, et al.,Pharmaceutical Biotechnology,vol. 6, Plenum Press, New York, 1995.
Roberts MJ, et al., J Pharm Sci, 1998, 87:1440-1445.
Romera SA, et al.,Vaccine,2001, 19:132-141.
Scharton-Kersten T, et al.Infect Immun,2000, 68:5306-5313.
Shen F, et al.,Vaccine,1999, 17:3039-3049.
Suharyono, et al.Lancet,1992, 340:689-694.
Talwar,Human Reproduction Update,1997, 3:301-310 at 307.
Visscher Ge, et al.,J Biomed Mater Res,1985, 19:349-365.
Wang CY, et al.,Proc. Nat. Acad. Sci.,USA, 1999, 96:10367-10372.
Weeratna RD, et al.,Vaccine,2000, 18:1755-1762.
Wright JC, et al.,J Controlled Release,2001, 75:1-10.
Result No. 1 of “rng ”Sequence Search Summary (PTO-892; mailed Feb. 17, 2005 in U.S. Appl. No. 10/076,674).
Result No. 1 of “rag ”Sequence Search Summary (PTO-892; mailed Feb. 17, 2005 in U.S. Appl. No. 10/076,674).
International Search Report Mailed Jan. 18, 2007 in related International Application No. PCT/US03/04711.
Decision by the Board of Patent Appeals and Interferences in related priority U.S. Appl. No. 10/076,674 mailed Jan. 6, 2010.
Morris, MC, et al. “A novel potent strategy for gene delivery using a single peptide vector as a carrier”Nucleic Acids Research, vol. 27, No. 17, 3510-3517 (1999).
Examiner's Requisition as issued in the related Canadian Patent Application No. 2,475,102; dated Jun. 3, 2010.
Oxenius, A., et al., “CpG-Containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-Cell peptide vaccines”,Journal of Virology, 73(5): 4120-4126. (1999).

Affiliated with

Also associated with

Rating

Stabilized synthetic immunogen delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stabilized synthetic immunogen delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized synthetic immunogen delivery system will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4262910